It was hypothesize that the AD biomarker could be categorized into brain β-amyloid (Aβ) plaque deposition (cerebrospinal fluid (CSF) Aβ1-42 and positron emission tomography (PET) Aβ imaging) and neurodegeneration (CSF tau, fluorodeoxyglucose-PET and structural magnetic resonance imaging (MRI)) [27]. Here, MAPT is linked to Alzheimer disease.